MedTrace Logo

the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)

NCT04835974 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-04-14

No results posted yet for this study

Summary

1- to find metabolic factors that correlate with the development of no reflow phenomenon that may help prevent its occurrence .

Conditions

  • No-Reflow Phenomenon

Interventions

DIAGNOSTIC_TEST

1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S

Blood samples were obtained before PCI, and the following parameters will be measured: 1. LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2. Glycemia will be assessed : RBS ( random blood sugar ) . 3. Serum Uric acid : S .UA

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2022-05-01
Completion
2022-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04835974 on ClinicalTrials.gov